NTRK gene fusion overexpression represents a rare but important genetic alteration in cancer, where pieces of chromosomes containing NTRK genes break off and attach to unrelated genes, creating abnormal proteins that drive tumor growth. While this fusion occurs in fewer than 1% of most solid tumors, it can be found across many different cancer types, and targeted treatments specifically designed to block these fusion proteins have shown remarkable results in clinical trials.

Understanding How Treatment Works for NTRK Fusion-Positive Cancers

When doctors discover that a patient’s cancer has NTRK gene fusion, it changes the entire approach to treatment. The goal is no longer just to slow down cancer growth with traditional chemotherapy, but to target the specific molecular abnormality that is driving the cancer. This fusion creates an unusual situation where the body produces abnormal proteins that act like a stuck accelerator pedal in a car, constantly signaling cells to grow and divide without stopping. Treatment aims to cut off this signal at its source.^[1]

The treatment strategy depends heavily on the cancer stage and where it has spread. For patients with cancer that can be surgically removed, treatment may combine surgery with targeted drugs. For those with advanced or metastatic disease—meaning cancer that has spread to distant parts of the body—targeted therapy becomes the primary focus. The beauty of treating NTRK fusion-positive cancers is that the same targeted drugs can work across different tumor types, whether the cancer started in the lung, breast, thyroid, or soft tissue. This is called a tumor-agnostic approach, meaning the treatment is based on the genetic abnormality rather than where the cancer originated.^[3]

Medical societies and cancer treatment guidelines now recommend testing for NTRK fusions in certain situations, especially in rare cancers where these fusions are more common, and in patients whose cancers have not responded to standard treatments. The decision to test should consider the likelihood of finding a fusion, the availability of targeted treatments, and what it would mean for the patient’s treatment plan.^[6]

Treatment duration varies significantly from patient to patient. Some people respond so well to targeted therapy that they can stay on the medication for years, as long as it continues to work and side effects remain manageable. Others may need to switch treatments if their cancer develops resistance. The key is continuous monitoring through imaging scans and sometimes repeat biopsies to track how well the treatment is working.^[8]

Standard Treatment Approaches for NTRK Fusion-Positive Cancers

Before the development of drugs specifically targeting NTRK fusions, patients with these cancers received standard chemotherapy appropriate for their tumor type. For example, someone with lung cancer would receive lung cancer chemotherapy, and someone with sarcoma would receive sarcoma chemotherapy. This approach often had limited success because it did not address the underlying driver of the cancer.^[11]

The breakthrough came with the development of TRK inhibitors—drugs specifically designed to block the abnormal proteins created by NTRK fusions. Two medications, larotrectinib and entrectinib, have been approved by regulatory authorities in the United States, Europe, and Japan. These approvals are unique because they allow the drugs to be used for any solid tumor type harboring NTRK fusions, regardless of where in the body the cancer originated.^[8]

Larotrectinib is typically given as a pill taken twice daily. The standard adult dose is 100 milligrams twice per day, though doctors may adjust the dose based on how well a patient tolerates it. In clinical trials, some patients needed dose reductions due to side effects but still achieved excellent responses at lower doses. One patient, for example, could not tolerate the full dose due to severe nausea and nerve pain but responded very well to 75 milligrams twice daily, experiencing a near-complete disappearance of lung and pleural tumors over 13 months.^[4]

Entrectinib is another TRK inhibitor that works similarly but has the added benefit of being able to cross into the brain more effectively. This makes it particularly useful for patients whose cancer has spread to the brain or for primary brain tumors with NTRK fusions. Like larotrectinib, entrectinib is taken orally, usually once daily.^[8]

The side effects of TRK inhibitors are generally milder than traditional chemotherapy. The most common problems patients experience include dizziness, nausea, fatigue, changes in liver function tests, weight gain, and mild numbness or tingling in the hands and feet. These side effects occur because TRK proteins have normal functions in the body, particularly in the nervous system. When the drugs block TRK proteins, they affect both cancer cells and some normal tissues. However, most patients find these side effects manageable, especially compared to chemotherapy.^[8]

Clinical trial results have been remarkable. Response rates—meaning the percentage of patients whose tumors shrank significantly—exceeded 75% in many studies. More importantly, these responses tended to be durable, with many patients maintaining disease control for extended periods. Some patients who were in wheelchairs or on supplemental oxygen before starting treatment were able to return to normal activities within weeks.^[12]

The duration of treatment with TRK inhibitors is individualized. Unlike chemotherapy, which is typically given for a set number of cycles, targeted therapy continues as long as it is working and the patient tolerates it well. Some patients have remained on these medications for several years without their cancer progressing. Regular monitoring with CT scans or other imaging tests, typically every few months, helps doctors assess whether the treatment continues to be effective.^[14]

Innovative Treatments Being Studied in Clinical Trials

While first-generation TRK inhibitors like larotrectinib and entrectinib have transformed treatment for NTRK fusion-positive cancers, researchers recognized early on that resistance could develop. This happens when the cancer finds ways to grow despite the drug, often by developing new mutations in the NTRK gene itself. To address this challenge, second-generation TRK inhibitors are being developed and tested in clinical trials.^[8]

One promising second-generation inhibitor is LOXO-195, now known by other designations in ongoing trials. This drug was specifically designed to overcome resistance mutations that develop in patients who initially responded to first-generation TRK inhibitors but whose cancers eventually progressed. The drug works by binding to the TRK protein in a different way, allowing it to block the protein even when resistance mutations are present. Early clinical trial results showed that some patients whose cancers had stopped responding to larotrectinib or entrectinib achieved new tumor responses when switched to LOXO-195.^[8]

Another second-generation inhibitor under investigation is TPX-0005. This medication is being tested in Phase I and Phase II clinical trials. Phase I trials focus primarily on determining what dose is safe and identifying potential side effects, while Phase II trials examine whether the drug actually works to shrink tumors. TPX-0005 was designed to have activity against multiple resistance mechanisms that can develop during treatment with first-generation TRK inhibitors.^[8]

Research has also explored whether other drugs that affect related pathways might help overcome resistance or enhance the effectiveness of TRK inhibitors. Since NTRK fusions activate multiple downstream signaling pathways in cells—including pathways involving proteins called MAPK/ERK and PI3K/AKT—some trials are investigating combinations of TRK inhibitors with drugs that block these other pathways. The theory is that blocking multiple pathways simultaneously might prevent cancer cells from finding alternative growth signals.^[10]

Interestingly, research has revealed that NTRK fusion-positive tumors may be more aggressive than other tumors, with enhanced ability to spread to distant sites. Studies using laboratory cell cultures showed that NTRK fusions promote a process called epithelial-mesenchymal transition (EMT), where cancer cells gain the ability to migrate and invade surrounding tissues more easily. Understanding this process has led researchers to investigate whether drugs targeting the migration machinery of cells might complement TRK inhibitors. In laboratory experiments, a TRK inhibitor called larotrectinib (also referred to as larolutinib in some research contexts) successfully blocked the migration and invasion abilities of NTRK fusion-positive cancer cells.^[2]

Clinical trials are being conducted in multiple countries including the United States, various European nations, China, and Japan. Patient eligibility typically requires confirmation of an NTRK fusion through molecular testing, evidence of advanced or metastatic cancer, and often previous treatment with at least one standard therapy. Some trials specifically enroll patients whose cancers have progressed on first-generation TRK inhibitors, while others are testing whether second-generation inhibitors might work as initial therapy.^[6]

One innovative area of investigation involves understanding which patients are most likely to develop resistance and why. Researchers have discovered that when cancer cells develop resistance, they often acquire specific mutations in the part of the NTRK protein where the drug binds—the kinase domain. These mutations change the shape of the protein just enough that first-generation inhibitors can no longer attach effectively. However, not all resistance mechanisms involve these mutations. Some tumors find entirely different growth pathways to bypass the blocked TRK signal. Ongoing research aims to identify these alternative resistance mechanisms so that appropriate combination therapies can be developed.^[8]

Most Common Treatment Methods

• First-Generation TRK Inhibitors
  • Larotrectinib is an oral medication taken twice daily, typically at 100 milligrams per dose, though adjustments may be made for tolerability while maintaining effectiveness
  • Entrectinib is administered once daily and has the advantage of crossing the blood-brain barrier, making it useful for brain metastases or primary brain tumors
  • Both drugs work by blocking the abnormal TRK fusion proteins that drive cancer growth, with response rates exceeding 75% in clinical trials
  • Side effects generally include dizziness, nausea, fatigue, liver function changes, weight gain, and mild nerve-related symptoms
  • Treatment continues as long as the cancer responds and side effects remain manageable, with some patients remaining on therapy for years
• Second-Generation TRK Inhibitors
  • LOXO-195 was designed specifically to overcome resistance mutations that develop during first-generation TRK inhibitor therapy
  • TPX-0005 is being tested in Phase I and II trials for patients with resistant disease
  • These medications bind to TRK proteins differently, allowing them to work even when resistance mutations are present
  • Early trial results show tumor responses in some patients whose cancers progressed on larotrectinib or entrectinib
• Traditional Chemotherapy
  • Before TRK inhibitors became available, patients received standard chemotherapy based on their specific tumor type
  • Chemotherapy remains an option for patients whose cancers do not harbor NTRK fusions or who develop resistance to TRK inhibitors
  • Response rates with chemotherapy are generally lower than with targeted TRK inhibitors for fusion-positive cancers
• Combination Therapies Under Investigation
  • Some clinical trials combine TRK inhibitors with drugs targeting downstream signaling pathways like MAPK/ERK or PI3K/AKT
  • The rationale is to block multiple growth signals simultaneously, potentially preventing or delaying resistance